MetaCap

Attovia Therapeutics (ATTO) vs Bambusa Therapeutics (BBTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Bambusa Therapeutics is the larger company by market cap ($815.1 million vs $690.3 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATTO-0.59%BBTX+6.74%
+15%+6%-4%
Oct 30, 20261 yearNov 20, 2026
ATTO-0.59%BBTX+6.74%
+8%+3%-1%
Oct 26, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATTO versus BBTX key metrics
MetricATTOBBTX
Share price$15.10$16.00
Market cap$690.26M$815.08M
1-day change-3.08%+2.89%
EPS (TTM)$-5.53$-1.73
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$28.00$17.65
52-week low$12.94$13.60
Distance from 52-week high-46.07%-9.35%
Analyst consensusstrong_buy—
Avg. price target upside+186.09%—
Average volume337.27K359.41K
Shares outstanding45.71M50.94M
Employees5026
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Attovia Therapeutics

ATTO stock →

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 50 employees

About Bambusa Therapeutics

BBTX stock →

Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 26 employees

ATTO vs BBTX FAQ

Which is bigger, Attovia Therapeutics or Bambusa Therapeutics?

Bambusa Therapeutics (BBTX) is larger, with a market capitalization of $815.08M compared with $690.26M for Attovia Therapeutics (ATTO).

Are Attovia Therapeutics and Bambusa Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons